Affiliation:
1. Department of Endocrinology and Metabolism West China Hospital of Sichuan University Chengdu China
2. Research Centre for Diabetes and Metabolism West China Hospital of Sichuan University Chengdu China
3. Department of Endocrinology and Metabolism Ziyang Central Hospital Ziyang Sichuan Province China
4. Department of Pathology Ziyang Central Hospital Ziyang Sichuan Province China
Abstract
AbstractSodium glucose cotransporter inhibitor (SGLTi) drugs have been widely used in clinical practice. In addition to their benefits in hyperglycemia, heart failure (HF), and kidney disease, their effects on obesity, metabolic dysfunction‐associated steatotic liver disease (MASLD, formerly named nonalcoholic fatty liver disease [NAFLD]), polycystic ovarian syndrome (PCOS), abnormal lipid metabolism, hyperuricemia, obstructive sleep apnea syndrome (OSAS), anemia, and syndrome of inappropriate antidiuresis (SIAD, formerly named syndrome of inappropriate antidiuretic hormone [SIADH]) have been explored. In this review, we searched the data of clinical randomized controlled trials (RCTs) and meta‐analyses of SGLTis in patients with diabetes from the PubMed library between January 1, 2020, and February 1, 2024. According to our review, certain SGLTis exhibit relatively superior clinical safety and effectiveness for treating the abovementioned diseases. Proper utilization of SGLTis in these patients can provide additional medication options for patients with different disease scenarios. However, studies of SGLTis in these diseases are relatively rare, with shortcomings such as small sample sizes and short intervention periods. Therefore, further large‐scale, long‐term, well‐designed studies are needed to clarify the findings.